Treatment Intensification: Strategies for Management in Practice – Post Survey

Now, how likely are you to use treatment intensification strategies that incorporate dual GLP1/GIP receptor agonist approaches for patients with T2D not already receiving these therapies, but who are still unable to meet target HbA1c levels and do not want to incorporate insulin into their disease management?(Required)




When choosing glucose-lowering therapies for a patient with less than optimally-controlled T2D, obesity, and ASCVD, who is receiving an SGLT2i, which of the following regimens should be the primary guiding principle in choosing a pharmacologic therapy for this patient?(Required)